Skip to main content

Table 1 Circulating tumor cells (CTCs) harboring the TP53 exon 4 mutation and wild-type allele

From: TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients

Patient ID TP53 mutation
  Isolated CTCs Isolated white blood cells (WBCs)
TRF001321 Single CTC (4994): TP53 R110 delC fs*13 Single WBC (5022): no mutation
Single CTC (2597): no mutation Single WBC (4940): no mutation
Single CTC (2319): no mutation Single WBC (4907): no mutation
Single CTC (2310): no mutation Single WBC (33): no mutation
Single CTC (50): TP53 R110 delG fs*13
Single CTC (2424): no mutation
Pool of 14 CTCs: TP53 R110 delC fs*13
TRF000155 Single CTC (925): TP53 R110 delC fs*13 Single WBC (491): no mutation
Cluster of 6 CTCs (1168): TP53 R110 delC fs*13 Single WBC (426): no mutation
Single CTC (475): TP53 R110 delCfs*13 Single WBC (337): no mutation
Cluster of 2 CTCs (476): TP53 R110 delC fs*13 Single WBC (77): no mutation
Cluster of 3 CTCs (346): TP53 R110 delC fs*13 Single WBC (261): no mutation
Cluster of 3 CTCs (300): TP53 R110 delC fs*13 Single WBC (289): no mutation
Single CTC (1944): TP53 R110 delC fs*13 Single WBC (1775): no mutation
Single CTC (1645): no mutation Single WBC (1564): no mutation
Single CTC (806): no mutation Single WBC (662): no mutation
Cluster of 2 CTCs (209): TP53 R110 delC fs*13
Cluster of 3 CTCs (816): no mutation
  1. CTCs and WBCs were isolated from two patients with metastatic triple-negative breast cancer. The cells shown in Figures 3 and 4 were studied; cell ids are indicated (in parenthesis). As control for the wild-type TP53 allele, four, and nine, WBCs from patients TRF001321 and TRF000155, respectively, were isolated and TP53 were sequenced; del, deletion; fs*13, frameshift mutation that creates a premature stop codon 13 aminoacids downstream.